|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun
Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chua MLK, Wee JTS, Hui EP and Chan ATC:
Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wee JT, Ha TC, Loong SL and Qian CN: Is
nasopharyngeal cancer really a ‘Cantonese cancer’? Chin J Cancer.
29:517–526. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cao D, Fan ST and Chung SS: Identification
and characterization of a novel human aldose reductase-like gene. J
Biol Chem. 273:11429–11435. 1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Scuric Z, Stain SC, Anderson WF and Hwang
JJ: New member of aldose reductase family proteins overexpressed in
human hepatocellular carcinoma. Hepatology. 27:943–950.
1998.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang R, Wang G, Ricard MJ, Ferris B,
Strulovici-Barel Y, Salit J, Hackett NR, Gudas LJ and Crystal RG:
Smoking-Induced Upregulation of AKR1B10 expression in the airway
epithelium of healthy individuals. Chest. 138:1402–1410.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang W, Li H, Yang Y, Liao J and Yang GY:
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits
pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Cancer Lett. 355:273–280. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang C, Yan R, Luo D, Watabe K, Liao DF
and Cao D: Aldo-keto reductase family 1 member B10 promotes cell
survival by regulating lipid synthesis and eliminating carbonyls. J
Biol Chem. 284:26742–26748. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu
G, Chen Z, Xu Y, Liu L, et al: A large-scale multicenter study
validates aldo-keto reductase family 1 member B10 as a prevalent
serum marker for detection of hepatocellular carcinoma. Hepatology.
69:2489–2501. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
van Weverwijk A, Koundouros N, Iravani M,
Ashenden M, Gao Q, Poulogiannis G, Jungwirth U and Isacke CM:
Metabolic adaptability in metastatic breast cancer by
AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Nat Commun. 10(2698)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Qu J, Li J, Zhang Y, He R, Liu X, Gong K,
Duan L, Luo W, Hu Z, Wang G, et al: AKR1B10 promotes breast cancer
cell proliferation and migration via the PI3K/AKT/NF-kappaB
signaling pathway. Cell Biosci. 11(163)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Huang C, Cao Z, Ma J, Shen Y, Bu Y,
Khoshaba R, Shi G, Huang D, Liao DF, Ji H, et al: AKR1B10 activates
diacylglycerol (DAG) second messenger in breast cancer cells. Mol
Carcinog. 57:1300–1310. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Ahmed SMU, Jiang ZN, Zheng ZH, Li Y, Wang
XJ and Tang X: AKR1B10 expression predicts response of gastric
cancer to neoadjuvant chemotherapy. Oncol Lett. 17:773–780.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hung JJ, Yeh YC and Hsu WH: Prognostic
significance of AKR1B10 in patients with resected lung
adenocarcinoma. Thorac Cancer. 9:1492–1499. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu W, Song J, Du X, Zhou Y, Li Y, Li R,
Lyu L, He Y, Hao J, Ben J, et al: AKR1B10 (Aldo-keto reductase
family 1 B10) promotes brain metastasis of lung cancer cells in a
multi-organ microfluidic chip model. Acta Biomater. 91:195–208.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fukumoto S, Yamauchi N, Moriguchi H, Hippo
Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H,
Yamamoto S, et al: Overexpression of the aldo-keto reductase family
protein AKR1B10 is highly correlated with smokers' non-small cell
lung carcinomas. Clin Cancer Res. 11:1776–1785. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chung YT, Matkowskyj KA, Li H, Bai H,
Zhang W, Tsao MS, Liao J and Yang GY: Overexpression and oncogenic
function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic
carcinoma. Mod Pathol. 25:758–766. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ko HH, Cheng SL, Lee JJ, Chen HM, Kuo MY
and Cheng SJ: Expression of AKR1B10 as an independent marker for
poor prognosis in human oral squamous cell carcinoma. Head Neck.
39:1327–1332. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ko HH, Peng HH, Cheng SJ and Kuo MY:
Increased salivary AKR1B10 level: Association with progression and
poor prognosis of oral squamous cell carcinoma. Head Neck.
40:2642–2647. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fang CY, Lin YH and Chen CL:
Overexpression of AKR1B10 predicts tumor recurrence and short
survival in oral squamous cell carcinoma patients. J Oral Pathol
Med. 48:712–719. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu J, Ban H, Liu Y and Ni J: The
expression and significance of AKR1B10 in laryngeal squamous cell
carcinoma. Sci Rep. 11(18228)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Taskoparan B, Seza EG, Demirkol S, Tuncer
S, Stefek M, Gure AO and Banerjee S: Opposing roles of the
aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell
Oncol (Dordr). 40:563–578. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zu X, Yan R, Pan J, Zhong L, Cao Y, Ma J,
Cai C, Huang D, Liu J, Chung FL, et al: Aldo-keto reductase 1B10
protects human colon cells from DNA damage induced by electrophilic
carbonyl compounds. Mol Carcinog. 56:118–129. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Sinreih M, Stupar S, Cemazar L, Verdenik
I, Frkovic Grazio S, Smrkolj S and Rizner TL: STAR and AKR1B10 are
down-regulated in high-grade endometrial cancer. J Steroid Biochem
Mol Biol. 171:43–53. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hojnik M, Frkovic Grazio S, Verdenik I and
Rizner TL: AKR1B1 and AKR1B10 as prognostic biomarkers of
endometrioid endometrial carcinomas. Cancers (Basel).
13(3398)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Guo Y, Luo W, Hu Z, Li J, Li X, Cao H, Li
J, Wen B, Zhang J, Cheng H, et al: Low expression of Aldo-keto
reductase 1B10 is a novel independent prognostic indicator for
nasopharyngeal carcinoma. Cell Biosci. 6(18)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
He YC, Shen Y, Cao Y, Tang FQ, Tian DF,
Huang CF, Tao H, Zhou FL, Zhang B, Song L, et al: Overexpression of
AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Cancer Biomark. 16:127–135. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bao YN, Cao X, Luo DH, Sun R, Peng LX,
Wang L, Yan YP, Zheng LS, Xie P, Cao Y, et al: Urokinase-type
plasminogen activator receptor signaling is critical in
nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle.
13:1958–1969. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Fan C, Wang J, Tang Y, Zhang S, Xiong F,
Guo C, Zhou Y, Li Z, Li X, Li Y, et al: Upregulation of long
non-coding RNA LOC284454 may serve as a new serum diagnostic
biomarker for head and neck cancers. BMC Cancer.
20(917)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tang XR, Li YQ, Liang SB, Jiang W, Liu F,
Ge WX, Tang LL, Mao YP, He QM, Yang XJ, et al: Development and
validation of a gene expression-based signature to predict distant
metastasis in locoregionally advanced nasopharyngeal carcinoma: A
retrospective, multicentre, cohort study. Lancet Oncol. 19:382–393.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Endo S, Matsunaga T and Nishinaka T: The
Role of AKR1B10 in physiology and pathophysiology. Metabolites.
11(332)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6(92)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu X, Hu Z, Qu J, Li J, Gong K, Wang L,
Jiang J, Li X, He R, Duan L, et al: AKR1B10 confers resistance to
radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma.
Int J Biol Sci. 17:756–767. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Matsunaga T, Suzuki A, Kezuka C, Okumura
N, Iguchi K, Inoue I, Soda M, Endo S, El-Kabbani O, Hara A and
Ikari A: Aldo-keto reductase 1B10 promotes development of cisplatin
resistance in gastrointestinal cancer cells through down-regulating
peroxisome proliferator-activated receptor-ү-dependent mechanism.
Chem Biol Interact. 256:142–153. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Morikawa Y, Kezuka C, Endo S, Ikari A,
Soda M, Yamamura K, Toyooka N, El-Kabbani O, Hara A and Matsunaga
T: Acquisition of doxorubicin resistance facilitates migrating and
invasive potentials of gastric cancer MKN45 cells through
up-regulating aldo-keto reductase 1B10. Chem Biol Interact.
230:30–39. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Matsunaga T, Yamaji Y, Tomokuni T, Morita
H, Morikawa Y, Suzuki A, Yonezawa A, Endo S, Ikari A, Iguchi K, et
al: Nitric oxide confers cisplatin resistance in human lung cancer
cells through upregulation of aldo-keto reductase 1B10 and
proteasome. Free Radic Res. 48:1371–1385. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yao Y, Wang X, Zhou D, Li H, Qian H, Zhang
J, Jiang L, Wang B, Lin Q and Zhu X: Loss of AKR1B10 promotes
colorectal cancer cells proliferation and migration via regulating
FGF1-dependent pathway. Aging (Albany NY). 12:13059–13075.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jin J, Liao W, Yao W, Zhu R, Li Y and He
S: Aldo-keto reductase family 1 member B 10 mediates liver cancer
cell proliferation through sphingosine-1-phosphate. Sci Rep.
6(22746)2016.PubMed/NCBI View Article : Google Scholar
|
